Clinical Trial Update: Study of VX-770 and Rifampin in Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 study update on VX-770 (ivacaftor) with rifampin in healthy male subjects to evaluate drug interaction potential in the context of cystic fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Kalydeco (Ivacaftor) (Ivacaftor)
• RIFAMPIN (RIFAMPIN)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED